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In addition to cholesterol lowering, 3-hydroxy-3-nethylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors limit
inflammatory changes associated with atherosclerosis. There
is also support for their use as inhibitors of progression in
chronic renal disease, irrespective of cause. In this study, their
capacity to limit acute renal inflammation was evaluated. For
this purpose, mice were treated with Simvastatin either prior
to, at the time of, or shortly after induction of nephrotoxic
nephritis. The severity of disease was determined by
evaluation of blood urea nitrogen (BUN), proteinuria, and
renal histologic changes. The reversibility of benefit was
evaluated by the administration of mevalonic acid along with
nephrotoxic serum (NTS) and Simvastatin The severity of the
acute nephritis, including proteinuria, elevated BUN, and
histologic changes, was ameliorated in a dose-dependent
manner, when Simvastatin was administered either prior to
NTS injection or at the time of NTS injection. By contrast,
Simvastatin did not alter the course of established nephritis.
Coadministration of mevalonic acid, the immediate substrate
following HMG-CoA reductase, abolished Simvastatin’s
renoprotective effect, indicating that the benefit is, at least
in part, due to interference with HMG-CoA reductase and
biosynthetic substrates downstream from the enzyme. These
findings provide the rationale for the evaluation of the
efficacy of HMG-CoA reductase inhibitors in patients with
recurrent forms of renal inflammation, to limit the severity of
acute exacerbations of disease, prevent renal scarring and
slow the rate of progression.
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Many immune-mediated forms of glomerulonephritis are
characterized by recurrent episodes of acute inflammation.
With time these conditions often lead to progressive fibrosis
and chronic renal failure. The efficacy of treatment with
intermittent immunosuppression for disease flares is limited
by timely recognition of disease activity, and severe inter-
stitial inflammation has often occurred by the time treatment
is initiated, worsening fibrosis. Continuous prophylactic
immunosuppressive and/or anti-inflammatory therapy to
prevent disease flares is often impractical due to substantial
side effects, and disease-specific agents are currently unavail-
able. Treatment with angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers are effective in slowing
the rate of progression to renal failure in general; however,
their major effects are neither anti-inflammatory nor
immunosuppressive.1
In clinical practice, 3-hydroxy-3-nethylglutaryl coenzyme
A (HMG-CoA) reductase-inhibiting drugs (statins) are
extremely useful cholesterol-lowering agents. Inhibi-
tion of HMG-CoA reductase leads to a reduced synthesis
of mevalonate. Downstream from mevalonate, the statins
have three main effects: (1) reduced synthesis of cholesterol
and isoprenoids, (2) reduced synthesis of farnesyl-diphospate
and farnesylation of Ras family proteins, and (3) reduced
geranylgeranylation of Rho family proteins. The reduced
production of Ras and Rho family proteins, small mem-
brane-bound GTPases, causes inhibition of downstream
signal transduction pathways leading to suppression of
the immune response by limiting T-cell maturation and
activation.2 Inhibition of macrophage recruitment and
function due to reduced expression of proinflammatory
mediators and cytokines (e.g. nuclear factor-kB, monocyte
chemoattractant protein-1, and various interleukins) has also
been reported,3–9 and this is likely a major contributor to
efficacy. These observations provide the rationale to use
statins as therapeutic agents to limit progression of
inflammatory diseases such as recurrent forms of glomer-
ulonephritis. Toward this end, we evaluated the efficacy of
Simvastatin treatment in the acute phase of nephrotoxic
nephritis.
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RESULTS
Simvastatin treatment inhibits nephrotoxic nephritis
Injection of nephrotoxic serum (NTS) into C57BL/6 mice
caused severe nephritis. These mice had heavy proteinuria,
hypercholesterolemia, oliguric acute renal failure, and
histological evidence of acute glomerulonephritis (Figures 1
and 2). By contrast, coadministration of Simvastatin was
associated with protection against nephritis (Figures 1 and 2).
The beneficial effect was most pronounced in mice that were
pretreated with Simvastatin, although simultaneous admin-
istration of Simvastatin was also protective. Simvastatin
treatment limited proteinuria, and it was associated with
significantly less fluid retention and weight gain; by day 6 of
the study, mice pretreated with Simvastatin gained only 2%
weight following the NTS injection as compared to 12.5% in
the simultaneously treated group and 35% in the untreated
group (Figure 1a). Simvastatin-treated mice had minimal
proteinuria and minimal elevations in blood urea nitrogen
(BUN) (Figure 1b).
Histologic evaluation confirmed the biochemical results
and revealed no evidence of glomerulonephritis in mice
treated with Simvastatin in doses greater than 10 mg/kg
(Figure 2). These findings were confirmed in three separate
experiments. All animals had intense staining for sheep IgG;
however, there was no evidence of a mouse anti-sheep
immune response, as determined by immunofluorescent
staining of the kidneys (data not shown).
The timing of the Simvastatin administration was crucial
to its beneficial effect. When Simvastatin treatment was
initiated at either 30 or 72 h after NTS administration, the
mice had severe nephritis with nephrotic syndrome and acute
oliguric renal failure that was indistinguishable from mice
that received NTS alone (data not shown).
The renoprotective benefits were dose dependent, as
Simvastatin in doses of 25 and 10 mg/kg were effective in
preventing the development of NTS nephritis, while the
1 mg/kg dose was not protective (Figure 3). Nephritis in the
latter group of mice was indistinguishable from the mice that
received NTS alone (P40.05). Simvastatin treatment did not
effect the deposition of sheep IgG within the glomeruli, as all
mice (in all groups) had strongly positive linear deposits of
IgG (4þ ) within the glomeruli. Simvastatin treatment alone
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Figure 1 | Simvastatin reduces the severity of NTS nephritis. (a) Weight: Fractional weight increase during the experiment (expressed as
d3/pretreatment-d1) and d6/pretreatment-d1; (b) 24 h urine protein (mg/day); (c) BUN levels (mg/dl); and (d) serum cholesterol (mg/dl).
*Po0.05; **Po0.001; NS, not significantly different. ’, pretreatment; post-treatment.
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lowered BUN in control mice (Po0.01), but it did not affect
s-cholesterol or cause proteinuria (Table 1).
Mevalonic acid reverses the inhibitory effect of Simvastatin
on nephrotoxic nephritis
Low serum cholesterol levels were not linked to the bene-
ficial, renoprotective effects on nephritis, as mice that received
Simvastatin and NTS simultaneously were protected from
nephritis and oliguric renal failure, despite elevated serum
cholesterol levels (Figure 1). This finding raised the possibility
that the renoprotective anti-inflammatory benefit observed was
independent from the cholesterol lowering. To more directly
address this issue, independent evaluations were performed.
Cholesterol lowering was compared to renoprotection, as
the dose of Simvastatin was reduced. The renoprotective
benefits were dose dependent, as described above. However,
although Simvastatin in doses of 25 and 10 mg/kg were
effective in preventing nephritis, serum cholesterol was not
lowered in the mice that received the 10 mg/kg dose. The
1 mg/kg dose of Simvastatin neither lowered cholesterol nor
was renoprotective.
Mevalonic acid administered with Simvastatin (and NTS)
completely reversed the protective effects of Simvastatin
(Figures 1–3). These mice developed severe nephritis indis-
tinguishable from mice that received only NTS. Within this
group two mice died. Mevalonic acid alone had no effect on
disease, as these mice developed severe nephritis, proteinuria,
and elevated BUN levels.
DISCUSSION
In the present study, the effects of Simvastatin on the acute
phase of NTS nephritis were evaluated. Simvastatin attenu-
ated the effects of nephritis when administered either prior to
or at the time of disease induction, although renoprotection
was greatest when it was administered prior to disease onset.
By contrast, Simvastatin administration after disease was
established was not effective. Simvastatin reduced the degree
of proteinuria, prevented elevation of BUN levels and limited
the pathologic effects induced by NTS. The effect appeared to
be unrelated to the quantity of sheep IgG deposited, as all of
the mice had intense staining for sheep IgG. The benefit also
appeared to be independent of its cholesterol lowering effect,
as low serum cholesterol levels were not consistently linked to
renoprotection. In this respect, the mice that received
Simvastatin and NTS simultaneously were protected from
nephritis, despite very high serum cholesterol levels.
The renoprotection was reversed by repletion of mevalonic
acid, indicating that the effect was mediated through
substrates generated downstream from mevalonate (Figure 4).
Elucidation of the precise pathway will require further study.
Although Simvastatin has been reported to increase renal
plasma flow,10 an effect shown by reduced BUN levels in the
Simvastatin control group, we do not believe that this was a
major contributing factor to the improved renal function
with Simvastatin. In all likelihood, this contribution to
glomerular filtration rate may have been offset by an
increased delivery of nephrotoxic antibodies to glomeruli.
Nevertheless, although clinical and pathologic evidence of
nephritis was reversed by the mevalonate, these animals did
not gain weight typical of the nephrotic syndrome. We
suspect that decreased food and water intake in these animals
was likely secondary to a direct effect of the mevalonic acid,
since there was clinical (proteinuria) and histologic evidence
of severe nephritis in the mice.
It is generally appreciated that statins slow progression of
renal scaring and limit atherosclerosis associated with chronic
renal failure. These benefits have been documented both in
patients and in animal models, and their efficacy is likely
related to the combined effects of lipid lowering, antiathero-
genic, and anti-inflammatory activities.11–15 Evidence that
renoprotection has a cholesterol-independent component
was raised by the findings of Katzav and co-workers, who
observed that Ras inhibition with farnesylthiosalicylate in
spontaneous murine lupus in MRL-lpr/lpr lupus mice
attenuated nephritis.16 However, distinction between immuno-
suppression and direct effect on the kidney was not
possible, since the treatment also reduced circulating
autoantibodies levels. The present study was designed to
eliminate the potential confounding, immunosuppressive
effects of Simvastatin on the adaptive immune response, as
the dose of NTS was similar in all groups, and the study was
ended prior to the usual appearance of an anti-sheep IgG
response. In this regard, the mice were not preimmunized
with sheep IgG to avoid the potential influence of
Simvastatin on the production of mouse anti-sheep IgG
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Figure 2 | Simvastatin reduces the severity of NTS nephritis.
Histology: (a): NTS injected mice with enlarged hypercellular
glomeruli (arrow) and dilated renal tubules with proteinaceus fluid
(arrowhead). There was also ATN in some specimens (not shown). (b)
By contrast, histology was normal in mice that received simvastatin
pretreatment. (c) Similarly, mice that received simvastatin with NTS
had less nephritis. (d) Mevalonic acid reverses to histology of NTS
nephritis. (e) Distribution of glomerular histology showing signifi-
cantly reduced severity of the glomerulonephritis by histological
criteria in the simvastatin-treated groups.
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antibodies, and spontaneous production of mouse anti-sheep
IgG is typically not apparent until 7–10 days after the
administration of sheep IgG. Both of these factors could have
confounded interpretation.
Evidence that statins and Ras inhibition limit acute renal
injury has been reported in other experimental diseases. In
the anti-thy 1 model, Clarke et al.17 observed that
farnesylthiosalicylate inhibition of Ras limited the severity
of nephritis. In these studies, antibody (anti-Thy 1)-
mediated, complement-dependent apoptosis of mesangial
cells results in proteinuria; this is typically followed by
mesangial proliferation and eventual restoration of renal
function. Farnesylthiosalicylate reduced both proteinuria and
proliferation. Statins were also found to attenuate the
reduction of glomerular filtration rate and pathologic effects
of ischemia-induced renal failure in mice, limit proteinuria
and macrophage infiltration in puromycin aminoglycoside-
induced nephrosis, and alter the course of passive Heymann
nephritis in rats. In the passive Heymann nephritis model,
Simvastatin reduced the expression of monocyte chemo-
attractant protein-1, and the benefit was enhanced by
angiotensin-converting enzyme inhibition.18 In puromycin-
induced nephrosis, Lovastatin reduced monocyte chemo-
attractant protein-1 and macrophage recruitment and
infiltration,4,7 whereas in the ischemia model, Lovastatin
caused an increased interleukin-6 expression and dampened
renal inflammation.3,9 Our studies extend these findings to
an acute inflammatory model of antibody-mediated, glo-
merulonephritis, involving infiltration of polymorphonuclear
cells and macrophages. Common to the benefits in all of
these models is the reduction in cellular recruitment and
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Figure 3 | Dose-dependent renoprotection of simvastatin in NTS nephritis. (a) Weight: Fractional weight increase over the experimental
period (d6/d0); (b) 24 h urine protein (mg/day); (c) BUN (mg/dl); and (d) serum cholesterol (mg/dl). Pretreatment values are compared to post-
treatment values and comparisons are carried out between post-treatment values in the three group (the bars). *Po0.05; **Po0.001; NS, not
significantly different. ’, Pretreatment; , post-treatment.
Table 1 | Effect of Simvastatin treatment of mice (n=5)
Pre-treatment Post-treatment P
Weight (g) 21.6 (1.3) 22.1 (0.8) NS
S-BUN (mg/dl) 37.5 (2.1) 24.9 (3.08) o0.001
S-cholesterol (mg/dl) 72.4 (13.3) 56.8 (19.5) NS
Histology score Not done Not done —
Proteinuria (mg/day) Not done Not done —
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infiltration, and it is consistent with the anti-inflammatory
actions of the drug.
In this regard, the acute anti-inflammatory and renopro-
tective effects of Simvastatin in the present study were, at
least in part, independent of lipid lowering, consistent with
other recent observations with HMG-CoA reductase inhi-
bitors. Simvastatin was observed to improve survival in mice
rendered septic by cecal ligation and perforation. In this
model, improved cardiac function was associated with
restored responsiveness to dobutamine and resistance to
bradykinin-induced stimulation of endothelial nitric oxide-
mediated reduction in coronary artery blood flow.19
Simvastatin has also been found to inhibit leukocytic
adhesion to the endothelium,20 inhibit major histocompat-
ibility complex-II expression on macrophages, leading to
altered maturation and activation of T cells.2,21 These latter
effects may contribute to improved outcome in human
cardiac transplantation.22,23 In the present study, although
effects on antigen presentation are unlikely to be a major
contributor to benefit, inhibition of cellular infiltration may
be operative, as statins were found to reduce macrophage
influx into inflamed tissues.7 These observations are
particularly relevant to the nephrotoxic nephritis model, as
both polymorphonuclear cells and macrophages infiltration
are involved in the pathogenesis of the acute phase of disease.
A potential mechanism is suggested by recent observations
that statins inhibit Fc receptor-mediated phagocytosis by
macrophages, since both macrophage infiltration and Fc
receptor dependence of nephritis has been found in this
model.24
Other related effects of statins may also have contributed.
They have been observed to inhibit expression of acute-phase
reactants, cytokines, and chemotaxic factors,3,5–9,14,25,26
which could also inhibit, cellular recruitment, limit activation
of monocytes, and reduce endogenous (renal) cell participa-
tion. This latter, conclusion is consistent with the findings of
Zager et al.27 and Johnson et al.,28 who suggested that the
renoprotection of statins in acute renal failure was due to
either anti-inflammatory properties or an effect of lowering
systemic lipid levels. Nevertheless, we intentionally designed
the study to both eliminate the potential immunosuppressive
effects of the agents and to limit the effects on renal
progression, per se.
Collectively, these statin-induced renoprotective effects
suggest that these drugs may be beneficial in the treatment of
human immune-mediated renal diseases. In addition to
limiting progression of chronic renal disease, we suggest that
patients suffering from recurrent episodes of acute renal
inflammation, such as those with lupus nephritis or IgA
nephropathy, may benefit. These patients are at risk of
progressive loss of renal function due to recurring flares of
acute disease. Pathologic evidence of both inflammation and
fibrosis are often present at the initiation of immuno-
suppressive therapy or on re-biopsy, consistent with the notion
that disease activity is present before initial presentation and
between overt disease flares. In these patients, statins have the
potential to limit disease severity during acute flares, reduce
the number of flares or/and thereby limit progressive loss of
renal function. Our results, therefore, provide the basis for
evaluating use of these drugs in patients with recurrent forms
of nephritis as a means to limit the rate of disease
progression.
MATERIALS AND METHODS
Animals; reagents
Female C57BL/6 mice were purchased from Jackson Laboratories.
All experiments were performed in mice of 8–12 weeks of age; the
mice weighed 17–22 g at induction of disease. All experiments were
conducted according to the NIH Guide for the Care and Use of
Laboratory Animals. NTS was prepared in sheep, using mouse
glomeruli, as described previously.29 Alexaflour 488-labeled donkey
anti-sheep IgG was purchased from Molecular Probes. Mevalonic
acid was purchased from Sigma-Aldrich (MO, USA). Simvastatin
was a generous gift from Merck (PA, USA).
Nephrotoxic nephritis protocols
The experimental design is presented in Figure 5. Sheep NTS, 10 ml/
kg, intraperitoneally, was administered as a single dose to the mice.
A single lot of NTS was used for all experiments. In preliminary
studies, the dose was determined so that all mice had intense (4þ )
linear sheep IgG deposits along the glomerular basement membrane,
light microscopic evidence of nephritis, and heavy proteinuria. All
mice were weighed prior to NTS dosing, at 3 and 6 days after NTS
administration. Simvastatin (4 mg/ml, pH 7.4) was administered to
mice in daily doses of 1, 10, or 25 mg/kg by intraperitoneal injection.
Simvastatin treatment was given in four different dosing regimens:
either starting on day 6 (n¼ 15), day 0 (n¼ 10), day þ 1 (n¼ 5)
or day þ 3 (n¼ 5) as compared to administration of the NTS.
Simvastatin alone was also given to C57BL/6 mice (n¼ 5), to serve
as controls. A cohort of mice (n¼ 10) was given mevalonic acid
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Figure 4 | Biosynthesis of cholesterol and GTPases.
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(25 mg/kg) with Simvastatin and NTS. Mevalonic acid was
administered by daily intraperitoneal injections. As a control,
mevalonic acid was also given with NTS (n¼ 10). Twenty-four
hours urinary protein excretion was determined prior to and 6 days
after NTS administration, by timed urine collection in metabolic
cages, using the Bio-Rad protein assay method (Bio-Rad Labora-
tories, Hercules, CA). BUN levels were measured using the Stanbio
enzymatic urea procedure (Stanbio Laboratory, Boerne, Texas).
Serum cholesterol levels were determined using a cholesterol reagent
set (Point Scientific, Lincoln Park, Michigan).
At the time of killing, one of the kidneys was snap-frozen,
sectioned (4 mm) and examined by direct immunofluorescence,
using fluoresceinated donkey anti-sheep IgG. The other kidney was
fixed in phosphate-buffered formalin, sectioned, and then stained
with hematoxylin and eosin. The histological severity of the
glomerulonephritis, which at this stage is mainly infiltrative, was
graded (0–4þ ) as described previously30 by a single observer
(MPM) who was blinded to the origin of the mice. Owing to the
small number of mice used in each group and the presence of small
interstitial infiltrates in some mice, kidneys with a histology score of
2 or less were termed ‘mild nephritis’, whereas mice with a score of
3 or more was called ‘severe nephritis’.
Statistical analyses
All values are presented as means7standard deviation. Statistical
analyses were performed using a nonparametric test, analysis of
variance, with comparison of individual groups. When appropriate,
a two-sided Student’s t-test was used. A P-value less than 0.05 were
taken to indicate statistical significance.
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